ZHOU Shihai, LUO Ping. Research Progress on Biologics in the Treatment of Primary Sjögren's Syndrome[J]. Chinese Journal of Modern Applied Pharmacy, 2022, 39(17): 2293-2300. DOI: 10.13748/j.cnki.issn1007-7693.2022.17.021
    Citation: ZHOU Shihai, LUO Ping. Research Progress on Biologics in the Treatment of Primary Sjögren's Syndrome[J]. Chinese Journal of Modern Applied Pharmacy, 2022, 39(17): 2293-2300. DOI: 10.13748/j.cnki.issn1007-7693.2022.17.021

    Research Progress on Biologics in the Treatment of Primary Sjögren's Syndrome

    • Primary Sjögren's syndrome(pSS) is a chronic autoimmune disease characterized by loss of salivary and lacrimal gland function. Traditional therapies including local symptomatic treatment, therapies based on immunosuppressant and so on, which are not satisfactory and also accompanied by high incidence of adverse reactions. In recent years, with the progress in understanding the pathogenesis of pSS, targeted biotherapy has emerged as a new option for pSS therapy. This review summarized the bio-targeted agents against pSS in recent years, focused on the targets, molecular biological mechanisms and clinical efficacy of different types of bio-targeted agents, in order to provide reference for the clinical treatment of pSS.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return